查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1418351

Daptomycin市場報告：2030 年趨勢、預測與競爭分析

Daptomycin Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

Daptomycin趨勢和預測

預計2024年至2030年，全球Daptomycin市場將以4.5%的複合年成長率成長。這個市場的主要促進因素是遭受皮膚和皮膚組織感染疾病的人口不斷增加、抗菌劑的使用不斷增加，以及敗血症等血液感染疾病的增加。全球Daptomycin市場前景廣闊，300mg和500mg市場有未來性。

Daptomycin市場洞察

Lucintel 預計，由於研發舉措的活性化，複雜皮膚組織感染疾病在預測期內仍將佔據更大的佔有率。

我們相信，由於其功效和穩定性，500mg 將繼續成為該市場的一大細分市場。

由於多項政府措施的興起，北美將在預測期內保持最大的市場規模。

常問問題

Q1.市場成長預測如何？

A1. 2024年至2030年，全球Daptomycin市場預計將以4.5%的複合年成長率成長。

Q2.影響市場成長的主要促進因素有哪些？

A2. 該市場的主要驅動力是遭受皮膚和皮膚組織感染疾病的人口不斷增加，其作為抗菌劑的使用不斷增加，以及膿毒症等血液感染疾病的增加。

Q3.市場的主要細分市場有哪些？

A3.Daptomycin市場未來性，300mg和500mg市場機會龐大。

Q4.市場上主要企業有哪些？

A4. 生產Daptomycin的主要企業如下。

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計，由於研發舉措的加強，複雜性皮膚組織感染疾病在預測期內仍將佔據更大的佔有率。

Q6. 未來五年預計哪個地區將成為最大的市場？

A6. 由於多項政府措施，北美在預測期內仍將是最大的。

Q7. 可以客製化報告嗎？

A7. 是的，Lucintel 提供 10% 的客製化服務，無需額外費用。

目錄

第1章執行摘要

第2章全球Daptomycin市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球Daptomycin市場趨勢（2018-2023）與預測（2024-2030）
  • 全球Daptomycin市場（按適應症）
    • 複雜的皮膚組織感染疾病
    • 菌血症
  • 按年齡層別分類的全球Daptomycin市場
    • 兒童
    • 成人
  • 全球Daptomycin市場實力
    • 300mg
    • 500mg

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球Daptomycin市場區域分佈
  • 北美Daptomycin市場
  • 歐洲Daptomycin市場
  • 亞太達托Daptomycin市場
  • 其他地區Daptomycin市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球Daptomycin市場成長機會（按適應症）
    • 按年齡層別分類的全球Daptomycin市場成長機會
    • 全球Daptomycin市場成長機會（按優勢）
    • 全球Daptomycin市場成長機會（按地區）
  • 全球Daptomycin市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球Daptomycin市場產能擴張
    • 全球Daptomycin市場的併購和合資企業
    • 認證和許可

第7章主要企業概況

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy's Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings
簡介目錄

Daptomycin Trends and Forecast

The future of the global daptomycin market looks promising with opportunities in the 300mg and 500mg markets. The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

A more than 150-page report is developed to help in your business decisions.

Daptomycin by Segment

The study includes a forecast for the global daptomycin by indication, age group , strength, and region.

Daptomycin Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Complicated Skin Structure Infections
  • Bacteremia

Daptomycin Market by Age Group [Shipment Analysis by Value from 2018 to 2030]:

  • Pediatric
  • Adult

Daptomycin Market by Strength [Shipment Analysis by Value from 2018 to 2030]:

  • 300mg
  • 500mg

Daptomycin Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Daptomycin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies daptomycin companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the daptomycin companies profiled in this report include-

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Daptomycin Market Insights

Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.

Within this market, 500mg will remain the larger segment due to its efficacy and stability.

North America will remain the largest over the forecast period due to growing several government initiatives.

Features of the Global Daptomycin Market

Market Size Estimates: Daptomycin market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Daptomycin market size by indication, age group , strength, and region in terms of value ($B).

Regional Analysis: Daptomycin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different indication, age group , strength, and regions for the daptomycin market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the daptomycin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for daptomycin market?

Answer: The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the daptomycin market?

Answer: The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

Q3. What are the major segments for daptomycin market?

Answer: The future of the daptomycin market looks promising with opportunities in the 300mg and 500mg markets.

Q4. Who are the key daptomycin market companies?

Answer: Some of the key daptomycin companies are as follows.

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Q5. Which daptomycin market segment will be the largest in future?

Answer: Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.

Q6. In daptomycin market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest over the forecast period due to growing several government initiatives.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the daptomycin market by indication (complicated skin structure infections and bacteremia), age group (pediatric and adult), strength (300mg and 500mg), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Daptomycin Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Daptomycin Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Daptomycin Market by Indication
    • 3.3.1: Complicated skin structure infections
    • 3.3.2: Bacteremia
  • 3.4: Global Daptomycin Market by Age Group
    • 3.4.1: Pediatric
    • 3.4.2: Adult
  • 3.5: Global Daptomycin Market by Strength
    • 3.5.1: 300mg
    • 3.5.2: 500mg

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Daptomycin Market by Region
  • 4.2: North American Daptomycin Market
    • 4.2.2: North American Daptomycin Market by Strength: 300mg and 500mg
  • 4.3: European Daptomycin Market
    • 4.3.1: European Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.3.2: European Daptomycin Market by Strength: 300mg and 500mg
  • 4.4: APAC Daptomycin Market
    • 4.4.1: APAC Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.4.2: APAC Daptomycin Market by Strength: 300mg and 500mg
  • 4.5: ROW Daptomycin Market
    • 4.5.1: ROW Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.5.2: ROW Daptomycin Market by Strength: 300mg and 500mg

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Daptomycin Market by Indication
    • 6.1.2: Growth Opportunities for the Global Daptomycin Market by Age Group
    • 6.1.3: Growth Opportunities for the Global Daptomycin Market by Strength
    • 6.1.4: Growth Opportunities for the Global Daptomycin Market by Region
  • 6.2: Emerging Trends in the Global Daptomycin Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Daptomycin Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Daptomycin Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceuticals Industries
  • 7.2: Merck
  • 7.3: Cipla
  • 7.4: Pfizer
  • 7.5: BE Pharmaceuticals
  • 7.6: Reddy's Laboratories
  • 7.7: Mylan
  • 7.8: Fresenius Kabi
  • 7.9: Nichi-Iko Pharmaceutical
  • 7.10: Novo Holdings